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Abstract
Background: Antipsychotic medications often have a variety of side effects, however, it is not well understood how
the presence of specific side effects correlate with adherence in a real-world setting. The aim of the current study was
to examine the relationship between these variables among community-dwelling patients with schizophrenia.
Methods: Data were analyzed from a 2007-2008 nationwide survey of adults who self-reported a diagnosis of
schizophrenia and were currently using an antipsychotic medication (N = 876). The presence of side effects was
defined as those in which the patient reported they were at least “somewhat bothered”. Adherence was defined as
a score of zero on the Morisky Medication Adherence Scale. To assess the relationship between side effects and
adherence, individual logistic regression models were fitted for each side effect controlling for patient
characteristics. A single logistic regression model assessed the relationship between side effect clusters and
adherence. The relationships between adherence and health resource use were also examined.
Results: A majority of patients reported experiencing at least one side effect due to their medication (86.19%).
Only 42.5% reported complete adherence. Most side effects were associated with a significantly reduced likelihood
of adherence. When grouped as side effect clusters in a single model, extra pyramidal symptoms (EPS)/agitation
(odds ratio (OR) = 0.57, p = 0.0007), sedation/cognition (OR = 0.70, p = 0.033), prolactin/endocrine (OR = 0.69, p =
0.0342), and metabolic side effects (OR = 0.64, p = 0.0079) were all significantly related with lower rates of
adherence. Those who reported complete adherence to their medication were significantly less likely to report a
hospitalization for a mental health reason (OR = 0.51, p = 0.0006), a hospitalization for a non-mental health reason
(OR = 0.43, p = 0.0002), and an emergency room (ER) visit for a mental health reason (OR = 0.60, p = 0.008).
Conclusions: Among patients with schizophrenia, medication side effects are highly prevalent and significantly
associated with medication nonadherence. Nonadherence is significantly associated with increased healthcare
resource use. Prevention, identification, and effective management of medication-induced side effects are
important to maximize adherence and reduce health resource use in schizophrenia.
Background
Schizophrenia is a chronic, often debilitating psychiatric
illness with a lifetime prevalence of approximately 1% of
the US population [1,2]. Typically manifesting in late
adolescence or early adulthood, schizophrenia can
disturb perception, cognition, emotions, and behavior
[3]. In addition to pronounced effects on the well-being
of patients [4] and their families [5], schizophrenia also
exacts an economic burden, estimated at almost $63 bil-
lion per year in the US in 2002 [6].
Numerous antipsychotic medications are available
with demonstrated efficacy in reducing the acute symp-
toms of schizophrenia, improving the well-being of
patients, and enabling somet ol i v em o r ep r o d u c t i v e
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medications are important to receive optimal benefits. A
review of dropout rates in clinical trials found that 28%-
55% of schizophrenia patients drop out of clinical trials
before the study is complete; dropout rates were higher
with classic antipsychotic medications compared with
second generation antipsychotic medications due to side
effects [8]. In the Clinical Antipsychotic Trial of Inter-
ventional Effectiveness (CATIE) study, 74% of patients
discontinued their initial study medication before 18
months [9]. Approximately half of patients with schizo-
phrenia take 70% or less of their medication [10]. Inade-
quate adherence to antipsychotic medications increases
the risk of relapse and associated healthcare utilization
and costs [11-13]. A review by Sun et al. (2007) esti-
mated that antipsychotic nonadherence in the US was
responsible for between $1.4 and $1.8 billion in rehospi-
talization costs alone [11].
Studies have suggested that antipsychotic medication
side effects are associated with lower levels of adherence
[14,15]. Clinicians’ ratings of side effects are also asso-
ciated with treatment discontinuation [16]. Specifically,
side effects such as medication-related obesity, distress
over weight gain, and cognitive impairment have been
associated with increased rates of nonadherence
[14,15,17,18]. Although other studies have examined
adherence in real-world settings [18], few have studied
the relationship between specific side effects and nonad-
herence. Moreover, there are no studies assessing the
relationship between patient-reported side effects and
self-reported adherence. This patient perspective is valu-
able as it provides insight into how the perception of
side effects is associated with specific non-adherent
behaviors; something that cannot be obtained from
objective assessments of adherence. The primary aim of
the current study is to assess the relationship between
patient-reported antipsychotic side effects and self-
reported medication adherence in a community-dwelling
sample of patients with schizophrenia. A secondary aim
is to assess the relationship between medication adher-
ence and self-reported health resource utilization.
Methods
Data source
We analyzed an existing cross-sectional dataset of
patients with schizophrenia (N = 1,083). This original
survey, conducted between December 2007 and Febru-
ary 2008, was initiated to understand the treatments,
attitudes, health behaviors, and health outcomes among
patients with schizophrenia. The data generated from
this survey has been used in several previous studies,
each of which has outlined the methods in some detail
[4,19]. Briefly, patients were convenience sampled in
one of two ways to participate in a self-administered
survey to create the dataset: (1) patients who reported
h a v i n gs c h i z o p h r e n i ai na nI n t e r n e t - b a s e dc o n s u m e r
panel (Lightspeed Research Ailment Panel) were ran-
domly sent an invitation to participate in a web-based
questionnaire via email, and (2) patients were also
recruited from grassroots campaigns and newspaper
advertising to arrive at a central interview facility to take
a paper copy of the survey instrument.
The Lightspeed Research Ailment Panel is an opt-in
Internet panel which recruits its members through a
v a r i e t yo fo n l i n es o u r c e s( e .g., online support groups,
etc.). Patients with schizophrenia who join the panel
provide detailed demographic information and agree to
participate in a modest number of periodic Internet-
based surveys. No sampling frame was used for patients
who were recruited outside the Internet panel. Patients
who responded to the study advertisements were phone
screened for eligibility. Those who reported they were
diagnosed with schizophrenia by a healthcare profes-
sional, were 18 years of age or older, and were able to
read and write English were eligible for this study.
For patients taking the survey online (N = 157), an
email address was provided for patients to ask any ques-
tions they may have about the survey. Similarly, for
patients taking the survey at an interview site (N = 926),
a facilitator was present to answer any questions. All
patients, regardless of methodology, provided informed
consent and were compensated for their participation.
Patients who completed the survey online were compen-
sated in the form of points, which can be exchanged for
small prizes through Lightspeed Research. Patients who
completed the survey offline received a $50 check as
compensation. The study protocol and questionnaire
were reviewed and approved by Essex IRB (Lebanon,
NJ).
Sample
The study sample was limited to patients who reported
that they were currently taking a prescription medica-
tion for schizophrenia (N = 876).
Study measures
Patient characteristics
Patient characteristics consisted of demographic data
and healthcare characteristics. All demographic data,
except age, were assessed as categorical variables and
included: gender (female vs. male), ethnicity (non-white
vs. white) marital status (married/committed relation-
ship vs. all else), education (some college education or
higher vs. no college education/less than college educa-
tion), employment status (employed full-time or part-
time vs. not employed), insurance status (insured vs.
uninsured), and poverty (annual household income less
than $20,000 vs. income $20,000 or greater). Health
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bid medical conditions, which included type I and type
II diabetes, high blood pressure, high cholesterol, heart
disease, migraine, liver disease, and HIV.
Medication side effects
Medication side effects were self reported. Patients cur-
rently taking a prescription medication to treat their
s c h i z o p h r e n i aw e r ea s k e d ,“In the past month, have you
experienced any of the following side effects from your
medication?“. Among patients who responded “yes” to
any of the listed side effects, they were asked “how both-
ered are you by these side effects?“. Responses included
“not at all bothered“, “not very bothered“, “somewhat
bothered“, “very bothered“,a n d“extremely bothered“.
Our pre-specified definition of a side effect included any
side effect in which the patient was somewhat, very, or
extremely bothered. Side effects were also clustered into
five pre-specified categories: “extra pyramidal symptoms
(EPS)/agitation” (insomnia, restlessness/feeling jittery,
agitation, and tremors); “sedation/cognition” (sedation,
difficulty thinking or concentrating, sleepiness, and diz-
ziness); “prolactin/endocrine” (decreased interest in sex,
sexual dysfunction, difficult or painful menstrual peri-
ods, male breast enlargement or secretions); “metabolic”
(weight gain, increase in blood glucose level); and “gas-
trointestinal (GI)” (nausea/vomiting and constipation).
Post-hoc sensitivity analyses used a higher threshold for
side effect definition of very or extremely bothered and
removed “agitation” from the EPS/agitation cluster due
to the potential confounding of agitation and restless-
ness associated with akathisia.
Medication adherence
Adherence to medications was assessed using the four-
item Morisky Medication Adherence Scale (MMAS)
[20], an instrument which has previously shown to have
strong evidence for reliability and validity [20]. The
MMAS items include the presence or absence of the fol-
lowing non-adherent behaviors: forgetting to take medi-
cation, careless at times about taking medication,
stopping medication when feeling better, and stopping
medication when feeling worse. For this study we used a
threshold of one or more items to identify nonadher-
ence; adherence was classified as reporting “no” for all
items. This approach has been reported in previous
schizophrenia research [19].
Health resource use
Health resource use included self-reported emergency
room (ER) visits (for mental and non-mental health-
related reasons) and hospitalizations (for mental and
non-mental health-related reasons) in the prior six
months. Each of these four outcomes was defined
dichotomously as yes (1 or more visits) vs. no (0 visits).
Prior research has suggested patient-reported measures
of resource use show good evidence for validity in com-
parison with objective measures [21-25].
Statistical analysis
Descriptive statistics were calculated to describe the
patient characteristics, side effect, and medication adher-
ence for the entire sample. Unadjusted comparisons of
patient characteristics between adherent and nonadher-
ent groups were conducted using chi-square tests and
ANOVA tests for categorical and continuous variables,
respectively.
To examine the relationship between side effects and
nonadherence, a logistic regression model was fitted for
each side effect adjusting for age, gender, ethnicity, edu-
cation, household income, and number of comorbidities.
A single logistic regression model was also fitted using
the five pre-specified side effect clusters, controlling the
same covariates. To assess the relationship between
adherence and health resource use, a logistic regression
model was fitted for each of the resource use outcomes,
controlling for age, gender, marital status, ethnicity, edu-
cation, household income, insurance and the number of
comorbidities. For all regression models, an a priori
threshold for statistical significance was set at p < 0.05.
The individual side effect models were also fitted
using the more restrictive definition of side effect pre-
sence ("very bothered” or “extremely bothered”). The
symptom cluster model was also fitted after removing
“agitation” from the EPS/agitation cluster in order to
assess the robustness of that cluster.
Results
The study sample consisted of 876 patients with schizo-
phrenia who reported they were currently taking a med-
ication to treat their condition. The mean age of the
sample was 43 years, approximately half of the sample
was male, and 61% was white (see Table 1). Over half of
the sample was unemployed and 71.7% were taking aty-
pical antipsychotics. The mostc o m m o n l yr e p o r t e ds i d e
effects that were at least moderately bothersome
included difficulty thinking/concentrating (32.2%), rest-
lessness/feeling jittery (28.2%), insomnia (28.4%), weight
gain (25.8%), and sleepiness (25.1%) (see Table 2).
The frequency of nonadherent behaviors (individual
items of the MMAS) are presented in Figure 1. Nearly
half of patients reported that they sometimes forget to
take their medication (48.4%). Only 42.5% of patients
responded “no” to all four nonadherent behaviors in the
MMAS. Table 3 summarizes bivariate comparisons
between characteristics of adherent and nonadherent
patients. Fewer adherent patients were married or had
any college education. There were no other significant
differences in patient characteristics between groups.
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side effect are presented in Figure 2. Most of the side
effects assessed were significantly associated with a
decreased likelihood of medication adherence. Sensitivity
analyses using the more restrictive definition of side
effect presence did not change overall model results
with respect to significance or magnitude (see Addi-
tional file 1: Figure S1).
Table 4 summarizes results of the logistic regression
model using five side effect clusters. Younger age,
unemployment, and higher education were all associated
with a lower likelihood of adherence. Similarly, all of the
side effect clusters except GI were associated with a
lower likelihood of adherence. The EPS/agitation cluster
had the strongest effect, with a 43% reduction in odds
of being adherent, followed by metabolic side effects
with a 36% reduction. Results of the sensitivity analysis
removing agitation from the EPS/agitation cluster did
not affect the significance or magnitude of the effect
(see Additional file 2: Table S1).
Patients reporting complete medication adherence
were significantly less likely to report a hospitalization
for a mental health reason (OR = 0.51; 95%CI: 0.35-
0.75, p = .0006), a hospitalization for a non-mental
health reason (OR = 0.43; 95%CI: 0.28-0.67, p = .0002),
or an ER visit for a mental health reason (OR = 0.60;
95%CI: 0.41-0.87, p = .008).
Discussion
In this cross-sectional survey of patients in the US with
schizophrenia, nearly 80% of patients reported at least
one side effect that was at least somewhat bothersome
Table 1 Sample demographics (N = 876)
n%
Gender
Male 432 49.3
Female 444 50.7
Ethnicity
White 536 61.2
Non-white 340 38.8
Education
Less than college 421 48.1
Some college or higher 455 51.9
Household income
Less than $20,000 506 57.8
$20,000 or more 370 42.2
Marital status
Single 665 75.9
Married/living with partner 211 24.1
Insurance
Managed care (HMO, PPO) 241 27.5
Medicare 364 41.6
Veterans Affairs Medical Center 41 4.7
State Medicaid (MediCal for CA residents) 350 40.0
No health insurance 61 7.0
Don’t know 16 1.8
Employment
Employed full time 129 14.7
Employed part time 163 18.6
Student 29 3.3
Retired 70 8.0
Not employed 484 55.3
Atypical Medication
On a atypical medication 628 71.7
Mean SD
Age 43.03 11.80
Number of comorbidities 1.27 1.30
Table 2 Medication side effects reported by current
medication users (N = 876)
Side effect present and
bothersome
n%
Difficulty thinking/concentrating 349 32.2
Restlessness/feeling jittery 305 28.2
Insomnia 307 28.4
Sleepiness 272 25.1
Weight gain 279 25.8
Decreased interest in sex 223 20.6
Agitation 240 22.2
Sedation 173 16.0
Dizziness 193 17.8
Constipation 175 16.2
Tremors 142 13.1
Sexual dysfunction 136 12.6
Nausea/vomiting 110 10.2
Difficult/painful menstrual periods 51 4.7
Male breast enlargement or secretions 15 1.4
Increased in blood glucose level 9 0.8
22.3% 24.2%
48.4%
30.4%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Stop taking 
medications when I 
feel worse
Stop taking 
medications when I 
feel better
Sometimes I forget to 
take my medication
Sometimes I'm 
careless when taking 
my medication
Figure 1 Prevalence of non-adherent behaviors from the
Morisky Medication Adherence Scale.
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plete adherence to their medications. There were few
differences in the characteristics of adherent and nonad-
herent patients. However, we observed consistently
strong relationships between medication side effects and
nonadherence. Our finding that cognitive-related side
effects and weight gain were associated with nonadher-
ence is consistent with prior research [17,18].
EPS/agitation-related side effects were the most
strongly associated with nonadherence, and were com-
monly reported. This is a striking finding because atypi-
cal antipsychotics are generally thought to have lower
risk for EPS compared to typical antipsychotics [26,27].
Though, it should be noted, not all patients in this
study were on an atypical medication the vast majority
were. Both EPS and endocrine side effects of antipsycho-
tic medications are mediated by dopamine receptor 2
(D2) blockade [28]. The mechanism behind metabolic
side effects to antipsychotics is less clear, but may be
related to histaminergic blockade, which is also impli-
cated in sedative side effects [28,29].
Aside from side effects, a few other variables were sig-
nificantly associated with adherence. Specifically,
patients who were older, less educated, and employed
were more likely to be adherent. Prior evidence has sug-
gested that longer illness duration is associated with
greater adherence [30]; therefore, age may be serving as
a proxy for years diagnosed. Employment may be ser-
ving as a proxy for level of functioning (i.e., patients
with improved functioning are more likely to be in the
labor force), as poor disease insight has been shown to
Table 3 Sociodemographic and patient characteristic differences between those adherent and non-adherent with their
medication for their schizophrenia
Non-adherent (n = 504) Adherent (n = 372)
n% n % p
Female 260 51.6 184 49.5 0.5344
Married 138 27.4 73 19.6 0.0069
Non-white 192 38.1 148 39.8 0.6127
Some college or higher 283 56.2 172 46.2 0.0037
Household income $20,000 or more 226 44.8 144 38.7 0.0685
Insured 455 90.3 344 92.5 0.2487
Employed 156 31.0 136 36.6 0.0838
Mean SD Mean SD p
Age 42.40 12.02 43.89 11.46 0.0651
Number of comorbidities 1.34 1.29 1.18 1.31 0.0861
 
Odds ratios based on multivariable logistic regression with adherence as dependent variable 
Adherence defined as a score of zero on the Morisky Medication Adherence Scale 
Side effect was reported as present and “somewhat”, “very”, or “extremely bothersome” 
95% Confidence Intervals are indicated 
Figure 2 Adjusted odds ratios for the impact of each side
effect on complete adherence. Odds ratios based on multivariable
logistic regression with adherence as dependent variable.
Adherence defined as a score of zero on the Morisky Medication
Adherence Scale. Side effect was reported as present and
“somewhat”, “very”,o r“extremely bothersome”. 95% Confidence
Intervals are indicated.
Table 4 The relationship between side effect clusters and
complete medication adherence
OR 95%
LCL
95%
UCL
p
Female 1.08 0.80 1.45 0.6209
Married 0.73 0.51 1.06 0.0942
Age 1.02 1.00 1.03 0.0283
Non-White 0.99 0.73 1.33 0.9244
Some college or higher 0.72 0.53 0.97 0.0324
Insured 1.33 0.79 2.24 0.2821
Employed 1.45 1.03 2.03 0.0313
Household income $20,000 or
more
0.83 0.60 1.15 0.264
Number of comorbidities 0.96 0.86 1.09 0.549
Agitation/EPS 0.57 0.41 0.78 0.0007
Sedation/Cognition 0.70 0.50 0.97 0.0331
Prolactin/Endrocrine 0.69 0.49 0.97 0.0342
Metabolic 0.64 0.46 0.89 0.0079
GI 0.79 0.55 1.11 0.1729
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few studies have uncovered a relationship between edu-
cation and adherence. Because of the lack of support in
the literature, it is possible education also serves as a
proxy for another unmeasured variable (e.g., negative
attitudes toward medications), though additional
research is warranted.
Consistent with previous studies [11], nonadherence
is a significant risk factor for hospital and emergency
room use. In our study, we found that both mental
health and non-mental health hospital use was
increased in nonadherent patients. Antipsychotic medi-
cations demonstrate high variability in their risk of
inducing various side effects, and this may be mediated
by differential affinities for D2, 5HT2A, and other
receptors [28,29]. Clinicians may be faced with the
challenge of choosing between medications with a
lower risk for EPS yet higher risk for metabolic com-
plications, and vice versa, but we find that both side
effects are associated with significant nonadherence
that may lead to both psychiatric and non-psychiatric
hospitalizations. Therefore, preventing, identifying, and
minimizing the frequency and severity of medication-
related side effects may lead to greater adherence and
fewer hospitalizations.
Limitations
This study has several limitations. Because all data were
self-reported, diagnoses, treatments, adherence levels,
and healthcare resource utilization were not confirmed
by clinicians, patient records, or administrative claims
data. Patients may have either underreported or overre-
ported their experience with side effects (perhaps attri-
buting a medication side effect to a symptom of a
comorbid condition or vice versa) and their level of
adherence. However, this patient perspective can still be
valuable. Regardless of the true reason for the experi-
enced “side effect”, a patient’s perception of the reason
for the side effect may be more important in predicting
adherence. Even if the side effect is not due to their
schizophrenia medication, attributing it as such can
result in greater non-adherence.
The cross-sectional design prevents robust ascertain-
ment of causality. Although the hypothesis was that the
presence of side effects leads to greater non-adherence
it is possible that non-adherence (particularly sudden
medication suspension followed by a full dose) can
increase the presence of side effects. It is also possible
that increasing adherence may lead to more side effects.
It is possible that unobserved confounding may have
influenced the observed results. For example, severity of
schizophrenia, polypharmacy, complexity of medication
regimen, medication costs, among other variables, are
likely associated with non-adherence but were not
included in the current study. Similarly, limited informa-
tion was available with respect to the number of non-
antipsychotic medications. The greater the number of
medications, the more difficult it may be for patients to
determine which side effects are due to which treat-
ments. Finally, the use of a convenience sample may
have resulted in a sample that does not generalize to the
community-dwelling population of patients with schizo-
phrenia, as all patients were willing and functionally
able to participate in survey research. The usage of both
online and offline sample sources was implemented to
ensure variability in patient types but these patient types
may not be representative of the larger population.
Conclusions
Side effects of antipsychotic medications are highly pre-
valent and significantly associated with lower adherence,
which is associated with increased healthcare resource
use. Prevention of, monitoring for, and minimizing med-
ication side effects may lead to better adherence and
improved outcomes.
Additional material
Additional file 1: Adjusted odds ratios for the impact of each side
effect on complete adherence with more restrictive definition of
side effect presence.
Additional file 2: The relationship between side effect clusters and
complete medication adherence, removing agitation from the
agitation/EPS cluster.
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